ArticleEJNMMI research2017
Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: a pilot study.
Article in EJNMMI research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 42 citations in OpenAlex.
- Preliminary Evidence That Cortical Amyloid Burden Predicts Poor Response to Antidepressant Medication Treatment in Cognitively Intact Individuals With Late-Life Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2021Trial
- Serum Amyloid β Oligomer May Predict Treatment Response in Middle-Aged and Late-Life Patients With Depression.Neuropsychopharmacology reports · 2026Observational
- Blood ATX(N) Biomarkers and Cognitive Dysfunction in Severe Mental Illnesses.International journal of molecular sciences · 2026Review
- Trajectories of late-life depression: insights from molecular imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- A genetic study of immunity in depression and interactions with childhood maltreatment.Translational psychiatry · 2026Article
- Luteolin and its antidepressant properties: From mechanism of action to potential therapeutic application.Journal of pharmaceutical analysis · 2025Review
- Differential neuropsychiatric associations of plasma biomarkers in older adults with major depression and subjective cognitive decline.Translational psychiatry · 2024Article
- Association between CNS-active drugs and risk of Alzheimer's and age-related neurodegenerative diseases.Frontiers in psychiatry · 2024Article
- Biological factors influencing depression in later life: role of aging processes and treatment implications.Translational psychiatry · 2023Review
- Article
- Plasma Amyloid-β dynamics in late-life major depression: a longitudinal study.Translational psychiatry · 2022Article
- Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer's disease.Human molecular genetics · 2021Article
- Molecular imaging of beta-amyloid deposition in late-life depression.Neurobiology of aging · 2021Article
- Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden: Findings From the Alzheimer's Disease Neuroimaging Initiative Depression Project.Biological psychiatry · 2021Article
- The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression.Journal of Alzheimer's disease : JAD · 2021Article
- From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer's Disease.Current neuropharmacology · 2021Review
- Diagnosing and Treating Depression in Patients with Alzheimer's Disease.Neurology and therapy · 2019Review
- Modifiable Risk Factors for Alzheimer's Disease.Frontiers in aging neuroscience · 2019Article
- Fluoxetine and Vortioxetine Reverse Depressive-Like Phenotype and Memory Deficits Induced by AβFrontiers in pharmacology · 2019Article
- Stopping Cognitive Decline in Patients With Late-Life Depression: A New Front in the Fight Against Dementia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLack of treatment response in patients with late-life depression is common. The role of brain beta-amyloid (Aβ) deposition in treatment outcome in subjects with late-life depression remains unclear. The present study aimed to investigate brain Aβ deposition in patients with major depressive disorder (MDD) with differing treatment outcomes in vivo using
resultsThe MDD patients with moderate-to-severe treatment resistance had higher
conclusionsThis study provided preliminary evidence that region-specific Aβ deposition was present in some (but not all) MDD patients, especially in those with moderate-to-severe treatment resistance, and their depressive symptoms may represent prodromal manifestations of Alzheimer's disease (AD). Depressive symptomatology in old age, particularly in subjects with a poor treatment response, may underscore early changes of AD-related pathophysiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.